Загрузка...
Development and targeted use of nilotinib in chronic myeloid leukemia
The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired re...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2761189/ https://ncbi.nlm.nih.gov/pubmed/19920910 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|